Altered cytokine levels in the blood and cerebrospinal fluid of chronic pain patients

Journal of Neuroimmunology

Volumn 195, Issue 1-2, 2008, Pages 157-163

  Backonja, Miroslav Misha ^a   Coe, Christopher L ^a   Muller, Daniel A ^a   Schell, Kathleen ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Cerebrospinal; CRPS; Cytokines; Fluid; Interleukin 1; Neuropathic pain; Neuropathy; Pain intensity; Soluble Tumor Necrosis Factor receptor

Indexed keywords

CYTOKINE; DESIPRAMINE; FENTANYL; GABAPENTIN; HYDROCODONE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 8; LAMOTRIGINE; LEVORPHANOL; METHADONE; MORPHINE; NORTRIPTYLINE; OXYCODONE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; ZONISAMIDE;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; FEMALE; FIBROMYALGIA; HUMAN; IMMUNE RESPONSE; MALE; NERVE INJURY; NEURALGIA; NEUROPATHY; PAIN ASSESSMENT; PERIPHERAL CIRCULATION; POLYNEUROPATHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; ANALYSIS OF VARIANCE; BLOOD GLUCOSE; CHRONIC DISEASE; CYTOKINES; FEMALE; GLUCOSE; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT;

EID: 41949109975     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.01.005     Document Type: Article

References (55)

1. Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Fact. Rev. 7 (1996) 231-240
2. Aderka D., Englemann H., Maor Y., Brakebusch C., and Wallach D. Stabilization of the bioactivity of tumour necrosis factor by its soluble receptors. J. Exp. Med. 175 (1992) 323-329
3. Alexander G.M., van Rijn M.A., van Hilten J.J., Perreault M.J., and Schwartzman R.J. Changes in cerebrospinal levels of pro-inflammatory cytokines in CRPS. Pain 116 (2005) 213-219
4. Backonja M.-M. Painful neuropathies. In: Loeser S.H., Butler, Chapman C.R., and Turk D.C. (Eds). Bonica's Management of Pain (2000), J.D. Lippincott Williams and Wilkins, Philadelphia, PA. 371-387
5. Backonja M.M. Defining neuropathic pain. Anesth. Analg. 97 (2003) 785-790
6. Backonja M.M., and Galer B.S. Pain assessment and evaluations of patients who have neuropathic pain. Neurol. Clin. 16 (1998) 775-790
7. Bell M.J., Kochanek P.M., Doughty L.A., Carcillo J.A., Adelson P.D., Clark R.S., Wisniewski S.R., Whalen M.J., and DeKosky S.T. Interleukin-6 and interleukin-10 in cerebrospinal fluid after severe traumatic brain injury in children. J. Neurotrauma 14 (1997) 451-457
8. Berger A., Dukes E.M., and Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J. Pain 5 3 (2004) 143-149
9. Bridges J.D., Thompson S.W., and Rice A.S. Mechanisms of neuropathic pain. Brit. J. Anaesth. 87 (2001) 12-26
10. Brisby H., Olmarker K., Larsson K., Nutu M., and Rydevik B. Proinflammatory cytokines in cerebrospinal fluid and serum in patients with disc herniation and sciatica. Eur. Spin. J. 11 1 (2002) 62-66
11. Daut R.L., Cleeland C.S., and Flanery R.C. Development of the Wisconsin brief pain questionnaire to assess pain in cancer and other diseases. Pain 17 2 (1983) 197-210
12. De Jongh F., Vissers K.C., Meert T., Booij L.H., De Deyne C.S., and Heylen R.J. The role of interleukin-6 in nociception and pain. Anesth. Analg. 96 (2003) 1096-1103
13. DeLeo J.A., and Yezierski R.P. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 90 (2001) 1-6
14. DeLeo J.A., Tanga F.Y., and Tawfik V.L. Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/hyperalgesia. Neuroscient. 10 1 (2004) 40-52
15. Diez-Ruiz A., Tilz G.P., Zangerle R., Baier-Bitterlich G., Wachter H., and Fuchs D. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur. J. Haematol. 54 (1995) 1-8
16. Elliot A.M., Smith B.H., Penny K.I., Smith W.C., and Chambers W.A. The epidemiology of chronic pain in the community. Lancet 354 9186 (1999) 1248-1252
17. Empl M., Renaud S., Erne B., Fuhr P., Straube A., and Schaeren-Wiemers N. TNF-alpha expression in painful and nonpainful neuropathies. Neurol. 56 (2001) 1371-1377
18. Galer B.S., and Jensen M.P. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurol. 8 (1997) 332-338
19. George A., Kleinschnitzs C., Zelenka M., Brinkhoof J., Stoll G., and Sommer C. Wallerian degeneration after crush or chronic constriction injury of the afferent sciatic nerve is associated with a depletion of endoneurial interleukin-10 protein. Exp. Neurol. 188 (2004) 187-191
20. Harden R.N., Bruehl S., Galer B.S., Saltz S., Bertram M., Backonja M., Gayles R., Rudin N., Bhugra M.K., and Stanton-Hicks M. Complex regional pain syndrome: are the IASP diagnostic criteria valid and sufficiently comprehensive?. Pain 83 2 (1999) 211-219
21. Ignatowski T.A., Covey W.C., Knight P.R., Severin C.M., Nickola T.J., and Spengler R.N. Brain derived TNFalpha mediates neuropathic pain. Brain Res. 841 (1999) 70-77
22. Hijmnas-Antonissen C., Wesseldjik F., Munnikes R.J.M., Huygen F.M.P.M., van der Miejden P., Hooijkaas H., and Zijlstra F.J. Muliplex bead array assay for detection of 25 soluble cytokines in blister fluid of patients with complex regional pain syndrome type 1. Mediat. Inflamm. 1 28398 (2006) 1-8
23. Huygen F.J., Niehof S., Zijlstra F.J., van Hagen P.M., and van Daele P.L. Successful treatment of CRPS with anti-TNF. J. Pain Sympt. Manag. 27 (2004) 101-103
24. Janig W., and Baron R. Is CRPS I a neuropathic pain syndrome. Pain 120 (2006) 227-229
25. Junger H., and Sorkin L.S. Nociceptive and inflammatory effects of subcutaneous TNFalpha. Pain 85 (2000) 145-151
26. Kanaan S.A., Poole S., Saade N.E., Jabbur S., and Safieh-Garabdian B. Interleukin-10 reduces the endotoxin-induced hyperalgesia in mice. J. Neuroimmunol. 86 (1998) 142-150
27. Knoblach S.M., and Faden A.I. Interleukin-10 improves outcome and alters proinflammatory cytokine expression after experimental traumatic brain injury. Exp. Neurol. 153 (1998) 143-151
28. Kotani N., Kudo R., Sakura Y., Sawamura D., Sessler D.I., Okada H., Nakayma H., Yamagata T., Yasujima M., and Matsuki A. Cerebrospinal fluid interleukin-8 concentrations and the subsequent development of postherpetic neuralgia. Am. J. Med. 116 (2004) 318-324
29. Krause S., and Backonja M.-M. Development of a neuropathic pain questionnaire. Clin. J. Pain 19 5 (2003) 306-314
30. Loetscher H., Steinmetz M., and Lesslauer W. Tumour necrosis factor: receptors and inhibitors. Cancer Cells 3 (1991) 221-226
31. Malemud C.J. Cytokines as therapeutic targets for osteoarthritis. Biodrugs 18 1 (2004) 23-35
32. Marchland F., Perreti M., and McMahon S.B. Role of the immune system in chronic pain. Nat. Rev. Neurosci. 6 (2005) 521-532
33. McMahon S.B., Cafferty W.B., and Marand F. Immune and glial factors as pain mediators and modulators. Exp. Neurol. 192 (2005) 444-462
34. In: Mersky H., and Bogduk N. (Eds). Classification of Chronic Pain (1994), IASP Press, Seattle
35. Milligan E.D., Soderquist R.G., Malone S.M., Mahoney J.H., Hughes T.S., Langer S.J., Sloane E.M., Maier S.F., Leinwand L.A., Watkins L.R., and Mahoney J.J. Intrathecal polymer-based interleukin-10 gene delivery for neuropathic pain. Neuron Glia Biol. 2 4 (2006) 293-308
36. Mygland A. Approach to the patient with chronic polyneuropathy. Acta Neurol. Scand. Suppl. 187 (2007) 15-21
37. Natelson B.H., Weaver S.A., Tseng C.L., and Ottenweller J.E. Spinal fluid abnormalities in patients with chronic fatigue syndrome. Clin. Diag. Lab. Immunol. 12 (2005) 52-55
38. Pinckard J.K., Sheehan K.C., Arthur C.D., and Schreiber R.D. Constitutive shedding of both p55 and p75 murine TNF receptors in vivo. J. Immunol. 158 (1997) 3869-3873
39. Reyes T.M., Fabry Z., and Coe C.L. Brain endothelial cell production of a neuroprotective cytokine, interleukin-6, in response to noxious stimuli. Brain Res. 851 (1999) 215-220
40. Romero R., Maymon E., Pacora P., Gomez R., Mazor M., Yooh B.H., and Berry S.M. Further observations on the fetal inflammatory response syndrome: a potential homeostatic role for the soluble receptors to tumor necrosis factor-alpha. Am. J. Obstet. Gynecol. 183 (2000) 1070-1077
41. Rudwaleit M., Yin A., Siegert S., Grolms M., Radbruch A., Braun J., and Sieper J. Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor-α, increase of interleukin-10, and predicted by the initial concentration of interleukin-4. Ann. Rheum. Dis. 59 (2000) 311-314
42. Sawada M., Suzumura A., Hosoya H., Marunouchi T., and Nagatsu T. Interleukin-10 inhibits both production of cytokines and expression of cytokine receptors in microglia. J. Neurochem. 72 (1999) 1466-1471
43. Schmader K.E. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin. J. Pain 18 (2002) 350-354
44. Sommer C., and Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci. Lett. 361 (2004) 184-187
45. Sommer C., Schmidt C., and Geroge A. Hyperalgesia in experimental neuropathy is dependent on the TNF-receptor I. Exp. Neurol. 151 (1998) 138-142
46. Uceyler N., Rogausch J.P., Toyka K.V., and Sommer C. Differential expression of cytokines in painful and painless neuropathies. Neurol. 69 (2007) 42-49
47. Uceyler N., Valenza R., Sock M., Schedle R., Gprotte G.U., and Sommer C. Reduced levels of anti-inflammatory cytokines in patients with chronic widespread pain. Arth. Rheum. 54 8 (2006) 2656-2664
48. Van de Beekt W.J.T., Remarque E.J., Westendorp R.G.J., and van Hilten J.J. Innate cytokine profile in patients with complex regional pain syndrome is normal. Pain 91 (2001) 259-261
49. Van Zee K.J., Kohno T., Fischer E., Rock C.S., Moldawer L.I., and Lowry S. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc. Natl. Acad. Sci. 1 (1992) 4845-4849
50. Wagner R., Janjigian M., and Myers R.R. Anti-inflammatory interleukin-10 therapy in CCI neuropathy decreases thermal hyperalgesia, macrophage recruitment, and endoneurial TNF- alpha expression. Pain 74 (1998) 35-42
51. Wallace D.J., Linker-Israeli M., Hallegua D., Silverman S., Silver D., and Weisman M.H. Cytokines play an aeitopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheum. (Oxford) 40 (2001) 743-749
52. Wasner G., Baron R., and Backonja M.-M. Post-traumatic painful neuralgias: complex regional pain syndromes (reflex sympathetic dystrophy and causalgia) - CRPS/RSD: clinical characteristics, pathophysiological mechanisms and therapy. Neurol. Clin. N. Am. 16 4 (1998) 851-868
53. Watkins L.R., and Maier S.F. Glia: a novel drug discovery target for clinical pain. Nature Rev. Drug. Discovery 2 (2003) 973-977
54. Watkins L., Wiertelak E.P., Goehler L.E., Smith K.P., Martin D., and Maier S.F. Characterization of cytokine induced hyperalgesia. Brain Res. 54 (1994) 15-26
55. Whalen M.J., Carlos T.M., Kochanek P.M., Wisniewski S.R., Bell M.J., Clark R.S., DeKosky S.T., Marion D.W., and Adelson P.D. Interleukin-8 is increased in cerebrospinal fluid of children with severe head injury. Crit. Care Med. 28 (2000) 929-934